Health Insurance (1994-1995 Pathology Services Table) Regulations (Cth)

Health Insurance (1994-1995 Pathology Services Table) Regulations

Statutory Rules 1994 No. 233 as amended

made under the

Health Insurance Act 1973

This compilation was prepared on 10 July 2001

taking into account amendments up to SR 1995 No. 155

[Note: These regulations were repealed by SR 1995 No. 281]

Prepared by the Office of Legislative Drafting,

Attorney-General’s Department, Canberra

Contents

Page

•
•
•

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

1Citation [see Note 1]

These Regulations may be cited as the Health Insurance (1994-1995 Pathology Services Table) Regulations.

2Commencement

These Regulations commence on 1 July 1994.

3Repeal of Health Insurance (1993-1994 Pathology Services Table) Regulations

Statutory Rules 1993 No. 270 are repealed.

4Pathology services table

The table of pathology services in the Schedule is prescribed for the purposes of subsection 4A (2) of the Health Insurance Act 1973.

ScheduleTable of pathology service

(regulation 4)

Part1Rules of interpretation1Interpretation of Table

(1)
In this Table:
patient episode means:
- (a)
  a pathology service or pathology services (other than a pathology service to which paragraph 1 (1) (b) refers) provided for a single patient whose need for the service or services was determined under subsection 16A (1) of the Act on the same day, whether the services:
  - (i)
    are requested by 1 or more practitioners; or
  - (ii)
    are described in a single item or in more than 1 item; or
  - (iii)
    are rendered by 1 approved pathology practitioner or more than 1 approved pathology practitioner; or
  - (iv)
    are rendered on the same day or on different days; or
- (b)
  a pathology service to which rule 4 refers that is provided in the circumstances set out in that rule that relates to the service.
recognised pathologist means a medical practitioner recognised as a specialist in pathology by a determination under section 3D or subsection 61 (3) of the Act.
serial examinations means a series of examinations requested on 1 occasion whether or not:
- (a)
  the materials are received on different days by the approved pathology practitioner; or
- (b)
  the examinations or cultures were requested on 1 or more request forms by the treating practitioner.
the Act means the Health Insurance Act 1973.
(2)
In these Rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16A (6) of the Act applies.
(3)
A reference in this Table by number to an item that is not included in this Table is a reference to the item that has that number in the general medical services table or the diagnostic imaging services table, as the case requires.
(4)
A reference to a Group in the Table includes every item in that Group.
(5)
For the purposes of this subrule — any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

1ACertain pathology services to be treated as one service

(1)
In this rule:
general practitioner means a medical practitioner who:
- (a)
  is not a consultant physician in any specialty; and
- (b)
  is not a specialist in any specialty.
set of pathology services means a group of pathology services:
- (a)
  that consists of services that are described in at least 4 different items; and
- (b)
  all of which are requested in a single patient episode; and
- (c)
  each of which relates to a patient who is not an admitted patient of a hospital; and
- (d)
  none of which is referred to:
  - (i)
    in item 66241, 66417, 69241, 73053 or 73055; or
  - (ii)
    in an item in Group P10 (Patient episode initiation) or Group P11 (Specimen referred).
(2)
If a general practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this rule.
(3)
If the fee specified in one item that describes any of the services in the set of pathology services is higher than the fees specified in the other items that describe the services in the set:
- (a)
  the pathology service described in the first-mentioned item is to be treated as one pathology service; and
- (b)
  either:
  - (i)
    the pathology service in the set that is described in the item that specifies the second-highest fee is to be treated as one pathology service; or
  - (ii)
    if 2 or more items that describe any of those services specify the second-highest fee — the pathology service described in the item that specifies the second-highest fee, and that has the lowest item number, is to be treated as one pathology service; and
- (c)
  the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.
(4)
If the fees specified in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees specified in the other items that describe the services in the set:
- (a)
  the pathology service in the set that is described in the item that specifies the highest fee, and that has the lowest item number, is to be treated as one pathology service; and
- (b)
  the pathology service in the set that is described in the item that specifies the highest fee, and that has the second-lowest item number, is to be treated as one pathology service; and
- (c)
  the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.
(5)
If pathology services are to be treated as one pathology service under paragraph 1A (3) (c) or paragraph 1A (4) (c), the fee for the one pathology service is the highest fee specified in any of the items that describe the pathology services that are to be treated as the one pathology service.

2Precedence of items

(1)
If a service is described:
- (a)
  in an item in general terms; and
- (b)
  in another item in specific terms;
only the item that describes the service in specific terms applies to the service.
(2)
Subject to subrule (3), if:
- (a)
  subrule (1) does not apply; and
- (b)
  a service is described in 2 or more items;
only the item that provides the lower or lowest fee for the service applies to the service.
(3)
If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first-mentioned item, whether or not the services described in the 2 items are requested separately.

3Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request

(1)
In subrule 3 (2), service includes assay, estimation and test.
(2)
Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:
- (a)
  the services are listed in the same item; and
- (b)
  the patient’s need for the services was determined under subsection 16A (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than one day.

4Services to which rule 3 does not apply

(1)
Rule 3 does not apply to:
- (a)
  a pathology service described in item 66201, other than an estimation of fructosamine or lithium; or
- (b)
  quantitative estimation, described in item 66365, of 1 or more fractions of neonatal bilirubin;
if:
- (c)
  the service is rendered in relation to a single specimen taken on each of not more than 4 occasions in a period of 24 hours; and
- (d)
  the service is rendered to a patient in a hospital unit where:
  - (i)
    the presence of 1 nurse is required for each group of not more than 4 patients; and
  - (ii)
    the condition of the patients is continuously observed in relevant respects; and
- (e)
  in order to render the service, an approved pathology practitioner who is a recognised pathologist has to arrange for a member of the laboratory staff of the approved pathology authority concerned to undertake duties in respect of the service that are in addition to the usual duties of the staff member; and
- (f)
  the account for the service is endorsed “Rule 3 Exemption”.
(2)
Rule 3 does not apply to any of the following pathology services:
- (a)
  estimation of prothrombin time in respect of a patient undergoing anticoagulant therapy;
- (b)
  quantitative estimation of lithium in respect of a patient undergoing lithium therapy;
- (c)
  a service described in item 65007 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;
- (d)
  a service described in item 65007 in relation to methotrexate, gold, sulfasalazine or penicillamine therapy of a patient;
- (e)
  a service described in item 66201 in relation to methotrexate therapy of a patient;
- (f)
  quantitative estimation of urea, creatinine and electrolytes in relation to:
  - (i)
    cis-platinum therapy of a patient; or
  - (ii)
    chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital;
if:
- (g)
  under a request for a service, no more than 6 tests are requested; and
- (h)
  the tests are performed within 6 months of the request; and
- (j)
  the account for the service is endorsed “Rule 3 Exemption”.
(3)
Rule 3 does not apply to a pathology service:
- (a)
  to which item 66221 applies; and
- (b)
  for which a specimen is collected on each of 3 days for the purpose of making a valid estimation; and
- (c)
  for which the account is endorsed “Rule 3 Exemption”.

5Item taken to refer only to the first service of a particular kind 5.

For the purposes of an item in Group P1 (Haematology):
(a)
if pathology services of a kind referred to in item 65017 or 65019 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during that period; and
(b)
if:
(i)
tests (except tests mentioned in item 65023) are carried out in relation to a patient episode; and
(ii)
specimen material from the patient episode is stored; and
(iii)
in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65023) are carried out on the stored material;
the later tests and the earlier tests are taken to be part of one patient episode.

6Certain items not to apply to a service referred by one pathology practitioner to another

(1)
In this rule:
designated pathology service means a pathology service in respect of tests relating to a single patient episode that are:
- (a)
  tests of the kind described in item 66235; or
- (b)
  tests of the kind described in item 66405; or
- (c)
  tests of the kind described in item 69229.
(2)
This rule applies in respect of a designated pathology service where:
- (a)
  an approved pathology practitioner (“practitioner A”) in an approved pathology authority:
  - (i)
    has been requested to render the designated pathology service; and
  - (ii)
    is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more (but not all) of the tests included in the service; and
  - (iii)
    requests an approved pathology practitioner (“practitioner B”) in another approved pathology authority to render the test or tests that practitioner A is unable to render; and
  - (iv)
    renders each test included in the service, other than the test or tests in respect of which the request mentioned in subparagraph (iii) is made; and
- (b)
  the tests mentioned in subparagraph (a) (iv) that practitioner A renders are not tests constituting a service described in item 66239, 66415 or 69239.
(2A)
Where this rule applies in respect of a designated pathology service:
- (a)
  item 66235, 66237, 66405, 66407, 66409, 66411, 66413, 69229, 69231, 69233, 69235 or 69237 (as the case requires) applies in respect of the test or tests rendered by practitioner A; and
- (b)
  where practitioner B renders a service under a request referred to in subparagraph (2) (a) (iii) — subject to subrule (2B), the amount specified in item 66241, 66417 or 69241 (as the case requires) is payable for each test that the service comprises.
(2B)
For the purposes of paragraph (2A) (b), the maximum number of tests to which item 66241, 66417 or 69241 applies is:
- (a)
  in the case of item 66241:

3 - X; or

(b)
in the case of item 66417 or 69241:

6 - X ;

where X is the number of tests rendered by practitioner A in relation to the designated pathology service in respect of which the request mentioned in that paragraph is made.
(3)
Items in Group P10 (Patient episode initiation) do not apply to the second-mentioned approved pathology practitioner in subrule (2).

6AItems not to be split

Except as stated in rule 6, the amount specified in an item is payable only to one approved pathology practitioner in respect of a single patient episode.

7Certain tests on stored material to be treated as part of the same patient episode

For the purposes of items in Group P2 (Chemical):
(a)
if a pathology service that involves the measurement of a substance in urine requires calculation of a substance/creatinine ratio, the service is taken to include the measurement of creatinine necessary for the calculation; and
(b)
if:
(i)
tests are carried out in relation to a patient episode; and
(ii)
specimen material from the patient episode is stored; and
(iii)
in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;
the later tests and the earlier tests are taken to be part of one patient episode.

7AItem 66317

The amount specified in item 66317 is not payable in respect of a pathology service described in the item unless at least one of the following paragraphs applies:
(a)
if the HDL cholesterol or apolipoprotein B/A1 ratio of the patient is requested to be determined because the patient has a serum cholesterol level >5.5 mmol/1 — the determination is performed on the sample that the serum cholesterol level determination for the patient was performed;
(b)
if the HDL cholesterol or apolipoprotein B/A1 ratio of the patient is requested to be determined because the patient has a fasting serum triglyceride level >2.0 mmol/1 — the determination is performed on the sample that the serum triglyceride level determination for the patient was performed;
(c)
the pathologist who renders the service has a written statement from the medical practitioner who requested the service that the patient is on a lipid lowering drug.

7BThyroid function testing

(1)
For the purposes of item 66329:
abnormal level of TSH means a level of TSH that is outside the normal reference range in respect of the particular method of assay used to determine the level.
(2)
Except where paragraph (a) of item 66329 is satisfied, the amount specified in the item is not payable in respect of a pathology service described in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subrule (3).
(3)
The written statement from the medical practitioner must indicate:
- (a)
  that the tests are required for a particular purpose, being a purpose specified in paragraph (b) of item 66329; or
- (b)
  that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or
- (c)
  that the patient is on drugs that interfere with thyroid hormone metabolism or function.

8Meaning of serial examinations or cultures

For the purposes of an item in Group P3 (Microbiology):
(a)
serial examinations or cultures means a series of examinations or cultures requested on 1 occasion whether or not:
(i)
the materials are received on different days by the approved pathology practitioner; or
(ii)
the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and
(b)
if:
(i)
tests are carried out in relation to a patient episode; and
(ii)
specimen material from the patient episode is stored; and
(iii)
in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;
the later tests and the earlier tests are taken to be part of one patient episode.

9Tests in Group P4 (Immunology) relating to antibodies

For the purposes of items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if:
(a)
tests are carried out in relation to a patient episode; and
(b)
specimen material from the patient episode is stored; and
(c)
in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;
the later tests and the earlier tests are taken to be part of one patient episode.

10Tests on biopsy material – Group P5 (Tissue Pathology) and Group P6 (Cytology)

(1)
For the purposes of items in Group P5 (Tissue Pathology):
- (a)
  biopsy material means all tissue (other than a bone marrow biopsy) received by an approved pathology practitioner from an operation, or a group of operations, performed on a patient at the same time; and
- (b)
  if:
  - (i)
    a pathology service that comprises the examination of biopsy material is rendered under any of those items; and
  - (ii)
    a further pathology service mentioned in any of those items is also rendered using that biopsy material;
those pathology services are taken to be 1 pathology service; and
- (c)
  cytology means microscopic examination of 1 or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant. In accordance with customary laboratory practice examination of a blood film and a bone marrow aspirate is excluded from this definition.
(2)
For the purposes of Groups P5 and P6 of the Pathology Services Table, services in Group P6 include any services described in Group P5 on the material submitted for a test in Group P6.
(3)
For the purposes of subrule 10 (2) — any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

11Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances

(1)
For the purposes of this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred):
institution means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:
- (a)
  disadvantaged children; or
- (b)
  juvenile offenders; or
- (c)
  aged persons; or
- (d)
  chronically ill psychiatric patients; or
- (e)
  homeless persons; or
- (f)
  unemployed persons; or
- (g)
  persons suffering from alcoholism; or
- (h)
  persons addicted to drugs; or
- (i)
  physically or mentally handicapped persons;
but does not include:
- (j)
  a hospital; or
- (k)
  a nursing home; or
- (l)
  accommodation for aged persons that is attached to a nursing home or situated within a nursing home complex.
licensed collection centre has the same meaning as in Part IIA of the Act.
prescribed laboratory means a laboratory operated by:
- (a)
  the Commonwealth; or
- (b)
  a State or internal Territory; or
- (c)
  an authority of a State or internal Territory; or
- (d)
  an Australian tertiary education institution.
specimen collection centre has the same meaning as in Part IIA of the Act.
treating practitioner has the same meaning as in paragraph 16A (1) (a) of the Act.
(2)
If a service described in an item in Group P10 or P11 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant one of those items does not apply to the service if:
- (a)
  the service is rendered upon a request made in the course of an out-patient service at a recognised hospital; or
- (b)
  the service is rendered upon a request made for a patient who is a private patient in a recognised hospital when the request is made; or
- (c)
  the pathology equipment of a recognised hospital, or a prescribed laboratory, is used rendering the service; or
- (d)
  a member of the staff of a recognised hospital, or a prescribed laboratory, participates in the service in the course of the member’s employment with the hospital or laboratory.
(3)
An item in Group P10 or P11 does not apply to a pathology service to which subsection 16A (7) of the Act applies.

(4)
An item in Group P10 or P11 does not apply to a pathology service unless at least one item in Groups P1 to P8 also applies to that service.
(5)
Subject to subrule (7), if one item in Group P10 applies to a patient episode, no other item in that Group applies to that patient episode.
(6)
An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.
(7)
If, in respect of the same patient episode:
- (a)
  services referred to in 1 or more items in Group P5 and one or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; and
- (b)
  services referred to in 1 or more items in Group P6 and one or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by another approved pathology practitioner in another approved pathology authority;
the fee specified in the applicable item in Group P10 is payable to both approved pathology practitioners.
(8)
If more than one specimen is collected from a person on the same day for the provision of pathology services:
- (a)
  in accordance with more than one request; and
- (b)
  in or by a single approved pathology authority;
only a single amount specified in the applicable item in Group P10 is payable for the services.
(9)
The amount specified in item 73921 is payable only once in respect of a single patient episode.

12Application of an item in Group P11 (Specimen referred) to a service excludes certain other items

If item 73921 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology provider who claimed item 73921 in respect of that patient episode.

13Circumstances in which an item in Group P11 (Specimen referred) does not apply

(1)
An item in Group P11 does not apply to a referral if:
- (a)
  a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and
- (b)
  the approved pathology authority to which the referral is made is related to the referring approved pathology authority.
(2)
An approved pathology authority is related to another approved pathology authority for the purposes of subclause (1) if:
- (a)
  both approved pathology authorities are employed (including employed under contract) by the same person, whether or not that person is also an approved pathology authority; or
- (b)
  either of the approved pathology authorities is employed (including employed under contract) by the other; or
- (c)
  if both of the approved pathology authorities are corporations — the approved pathology authorities are related corporations within the meaning of the Corporations Law; or
- (d)
  the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities).

14Abbreviations

(1)
The abbreviations in Part 3 of this Table may be used to identify particular pathology services or groups of pathology services.
(2)
The names of services not listed in Part 3 of this Table must be written in full.

Part2Services and fees

Item	Pathology service	Fee ($)
Group P1 — Haematology
65001	Erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, or reticulocyte count — 1 or 2 tests	5.65
65003	3 or more tests described in item 65001, andcalculation or measurement of cell index or indices	7.75
65005	Examination of blood film, or 5 part differential cell count, or both 5 part differential cell count and examination of blood film, including (if performed): (a) a service described in item 65027; and (b) any of the following services: (i) examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron; (ii) examination of a blood film with alpha-naphthyl acetate esterase, chloroacetate esterase, neutrophil alkaline phosphatase, nitroblue tetrazolium, periodic acid Schiff or Sudan Black stains; (iii) Kleihauer test for HbF on blood film	10.25
65007	Full blood examination (consisting of the services described in items 65003 and 65005)	17.20
65009	Haemolysis or metabolic enzymes — assessment by: (a) erythrocyte autohaemolysis test; (b) erythrocyte fragility test; (c) sugar water test; (d) erythrocyte metabolic enzyme test; (e) heat denaturation test; (f) isopropanol precipitation test; (g) acid haemolysis test; and (h) quantitation of muramidase in serum or urine; 1 or more tests	23.60
65011	Haemoglobinopathy, tests for the diagnosis of, consisting of haemoglobin electrophoresis and 2 of: (a) examination for HbH; or (b) quantitation of HbA2; or (c) quantitation of HbF; including a service described in item 65001, 65003, 65005 or 65007 (if performed)	36.75
65013	Bone marrow trephine biopsy — histopathological examination of sections of bone marrow, including (if performed): (a) examination of aspirated material; and (b) special stains or immunochemical techniques (if any); and (c) a service described in item 65001, 65003, 65005, 65007 or 65015	112.90
65015	Bone marrow — examination of aspirated material (including clot sections where necessary), including (if performed): (a) special stains or immunochemical techniques (if any); and (b) a service described in item 65001, 65003, 65005 or 65007	82.00
65017	Blood grouping (including back-grouping if performed) — ABO and Rh (D antigen)	9.90
65019	Blood grouping — Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system — 1 or more systems, including a service described in item 65017 (if performed)	19.75
65021	Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including: (a) identification and quantitation of antibodies detected; and (b) (if performed) a service described in item 65001, 65003, 65005 or 65007	36.75
65023	Compatibility tests — all tests performed on any1 day, including: (a) all grouping checks of patient and donor; and (b) examination for antibodies, and, if necessary, quantitation of any antibodies detected; and (c) a service described in item 65001, 65003, 65005, 65007, 65017 or 65021 (if performed)	99.75
65025	Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)	16.25
65027	1 or more of the following tests: (a) direct Coombs test; (b) qualitative or quantitative test for cold agglutinins or heterophile antibodies; (c) qualitative spectroscopic examination of blood for abnormal haemoglobins; (d) qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test)	8.95
65029	Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of: fibrinogen degradation products, fibrin monomer or D-dimer — 1 test	12.40
65031	2 tests described in item 65029	16.40
65033	3 tests described in item 65029	20.40
65035	4 or more tests described in item 65029	24.40
65037	Quantitation, by 1 or more techniques, of: plasminogen, antithrombin III, Protein C, Protein S, heparin cofactor II euglobulin clot lysis time and test for lupus anticoagulant — 1 to 3 tests	24.35
65039	4 or more tests described in item 65037	77.35
65041	Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance — 1 or more tests	48.70
65043	Heparin quantitation when monitoring a patient on subcutaneous heparin or low molecular weight heparin — 1 or more tests	32.50
65045	Quantitation of Von Willebrand’s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, or Passovy factor — 1 test	32.45
65047	2 tests described in item 65045	46.75
65049	3 or more tests described in item 65045	61.05
Group P2 — Chemical
66201	Quantitation in serum, plasma, urine or other body fluid, by any method except reagent strip (with or without reflectance meter or electrophoresis) of: alanine aminotransferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total), bilirubin (any fractions), calcium (total, dialysed or ionised), chloride, creatine kinase, creatine kinase isoenzymes (if not performed as described in item 66249), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, urate or urea — 1 test	9.55
66203	2 tests described in item 66201	11.60
66205	3 tests described in item 66201	13.65
66207	4 tests described in item 66201	15.70
66209	5 tests described in item 66201	17.75
66211	6 or more tests described in item 66201	19.80
66213	Test by any method (except reagent strip or dip-stick): (a) for the presence of: (i) the following urine constituents — bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen; or (ii) cryoglobulins or cryofibrinogen in plasma; or (b) of pH of body fluids other than urine (not including urine acidification test); 1 or more tests	9.70
66215	Quantitation of cryoglobulins or cryofibrinogen following their detection in a test described in item 66213, including that service — 1 or more tests	14.70
66221	Test for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces) by: (a) an immunological method; and (b) a chemical method (except reagent strip or dip-stick); each test, to a maximum of 3 tests taken on separate days in a 28 day period	8.80
66223	Osmolality, estimation by osmometer, in serum or in urine — 1 or more tests	24.35
66225	Quantitation of: (a) blood gases (including pO2, oxygen saturation and pCO2); and (b) bicarbonate and pH; including any other measurement (e.g., haemoglobin or potassium) or calculation performed on the same specimen — 1 or more tests on 1 specimen	33.25
66227	Quantitation of blood gases, bicarbonate and pH as described in item 66225 on each specimen in excess of 1 to a maximum of 6 specimens within any 1 day	8.80
66229	Calculus, analysis of 1 or more	30.20
66231	All qualitative and quantitative tests on blood, urine or other body fluid for: (a) a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or (b) ingested or absorbed toxic chemicals; including a service described in item 66235, 66237 or 66239 (if performed), but excluding: (c) the surveillance of sports people and athletes for performance improving substances; and (d) the monitoring of patients participating in a drug abuse treatment program	41.00
66235	Quantitation, not elsewhere described in this Table by any method or methods, in blood or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken — 1 test (Item is subject to rule 6)	20.45
66237	2 tests described in item 66235 (Item is subject to rule 6)	28.65
66239	3 or more tests described in item 66235	36.85
66241	Tests described in item 66235, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 (Item is subject to rule 6)	8.20
66243	Amniotic fluid, spectrophotometric examination of, and quantitation of: (a) lecithin/sphingomyelin ratio; or (b) palmitic acid, phosphatidylglycerol or lamellar body phospholipid; 1 or more tests	32.50
66247	Electrophoresis (including quantitation), of serum and either or both urine or other body fluid all collected within a 28 day period, to demonstrate protein lasses or presence of paraprotein, including the preliminary quantitation of: (a) total protein, albumin and globulin; or (b) total relevant enzyme activity; 2 or more tests	49.85
66249	Electrophoresis, quantitative or qualitative, of serum, urine or other body fluid to demonstrate: (a) protein classes; or (b) presence and amount of paraprotein; or (c) the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase; including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity	35.20
66250	Electrophoresis, quantitation or qualitative, of serum, for demonstration of lipoprotein subclasses, if the cholesterol is 6.5 mmol/l and triglyceride 3.0 mmol/l or in the diagnosis of types III and IV hyperlipidaemia — each episode to a maximum of 2 episodes in a 12 month period	30.20
66255	Alpha-1-acid glycoprotein, alpha-1-antitrypsin, or alpha-2-macroglobulin — quantitation in serum, urine or other body fluid — 1 or more tests	19.90
66257	C-1 esterase inhibitor — quantitation	19.90
66258	C-1 esterase inhibitor — functional assay	44.50
66261	CA-125 antigen, CA-15.3 antigen, CA-19.9 antigen, carcinoembryonic antigen (CEA), mammary serum antigen, mucin-like carcinoma-associated antigen (1 or more fractions), neuron-specific enolase, or thyroglobulin in serum or other body fluid, in the monitoring or confirmation of malignancy — quantitation — 1 test	19.90
66262	2 or more tests described in item 66261	36.65
66263	Iron studies, consisting of quantitation of: (a) serum iron; (b) transferrin or iron binding capacity; and (c) ferritin	36.70
66265	Serum B12 or serum folate — 1 or more tests within a 28-day period	24.35
66267	Red cell folate and serum B12, and, if required, serum folate, to a maximum of 3 episodes in a 12-month period	44.45
66269	Vitamins — quantitation of vitamins A, B1, B2, B3, B6, C, and E in blood, urine or other body fluid — 1 or more tests within a 6-month period	30.20
66271	Vitamin D or D fractions — 1 or more tests	30.20
66277	Quantitation of aluminium (except if item 66325 applies), arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, or strontium, in blood, urine or other body fluid or tissue — 1 or more tests in a 6-month period	35.35
66279	Blood lead quantitation (other than for occupational health screening purposes) to a maximum of 3 tests in a 6-month period — each test	30.20
66281	Porphyrins (1 or more fractions), catecholamines (1 or more fractions), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), or phenylacetic acid (PAA) — quantitation — 1 or more tests	39.45
66283	Quantitation of: (a) faecal fat; or (b) breath hydrogen in response to loading with disaccharides; 1 or more tests within a 28-day period	39.45
66285	Enzymes — quantitation of 1 or 2 in solid tissue or issues other than blood elements	39.45
66287	Quantitation of 3 to 5 enzymes as described in item	73.45
66289	Quantitation of 6 or more enzymes as described in item 66285	97.45
66293	Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and quantitation of hormones	48.70
66295	Personal performance by a recognised pathologist of 1 or more of the following: (a) growth hormone suppression by glucose loading; (b) growth hormone stimulation by exercise; (c) dexamethasone suppression test; (d) L-dopa stimulation of growth hormone	11.60
66297	Personal performance by a recognised pathologist of 1 of the following: (a) gonadotrophin releasing hormone stimulation test; (b) synacthen stimulation test; (c) glucagon stimulation test with C-peptide measurement; (d) pentagastrin stimulation of thyrocalcitonin release; (e) secretin stimulation of gastrin release; (f) insulin hypoglycaemia; (g) arginine infusion	38.70
66299	Personal performance by a recognised pathologist of 2 or more tests described in item 66297	61.90
66315	Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast — 1 or more tests	78.90
66317	Quantitation of HDL cholesterol or apolipoprotein B/A1 ratio in a patient who: (a) has a serum cholesterol level>5.5mmol/1; or (b) has a fasting serum triglyceride level>2.0mmol/1; or (c) is on a lipid lowering drug prescribed by a medical practitioner; each episode to a maximum of 4 episodes in a 12 month period (Item is subject to rule 7A)	12.35
66319	Quantitation of glycosylated haemoglobin performed in the management of established diabetes — each test to a maximum of 4 tests in a 12-month period	16.60
66321	Quantitation, in the 2nd trimester of pregnancy, of alpha fetoprotein, human chorionic gonadotrophin, oestriol and any other substance to detect foetal abnormality, including a service described in 1 or more of items 66353, 66373, 73527 and 73529 (if performed) — 1 patient episode in a pregnancy	54.50
66323	Test for tryptic activity in faeces in the nvestigation of diarrhoea of longer than 4 weeks duration in children under 6 years old	11.00
66325	Quantitation of serum aluminium in a patient in a renal dialysis program — each test	35.35
66327	TSH — quantitation, requested as a preliminary test to thyroid function testing	31.55
66329	Thyroid function tests (comprising the service described in item 66327 and 1 or more of the following tests — estimation of free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin) in respect of a patient, if at least one of the following conditions is satisfied: (a) the patient has an abnormal level of TSH;	41.00
(b) the tests are performed for the purpose of: (i) monitoring thyroid disease in the patient; or (ii) if the patient is in a hospital — investigating thyroid function in the patient; or (iii) investigating dementia or psychiatric illness of the patient; or (iv) investigating amenorrhoea or infertility of the patient; (c) the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; (d) the patient is on drugs that interfere with thyroid hormone metabolism or function (Item is subject to rule 7B)
66331	Quantitation (except by reagent strip with or without reflectance meter or electrophoresis) of cholesterol or triglycerides or both in serum, plasma, urine or other body fluid	11.40
66335	A service described in item 66331 and 1 test described in item 66201	13.65
66337	A service described in item 66331 and 2 tests described in item 66201	15.70
66339	A service described in item 66331 and 3 tests described in item 66201	17.75
66341	A service described in item 66331 and 4 or more tests described in item 66201	19.80
66343	Detection or quantitation or both (not including the detection of nicotine and metabolites in smoking withdrawal programs) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient: (a) participating in a drug abuse treatment program; or (b) being treated for drug effects; including all tests on blood, urine or other body fluid — each episode, to a maximum of 21 episodes in a 12-month period	20.50
66353	Quantitation in serum or other body fluids of alpha fetoprotein, except if requested as part of item 66321	19.90
66355	Ferritin — quantitation, except if requested as part of iron studies	19.90
66357	Prostate specific antigen or prostatic acid phosphatase — quantitation in the confirmation or monitoring of malignancy — 1 test	19.90
66359	2 tests described in item 66357	36.65
66361	Beta-2-microglobulin, caeruloplasmin, haptoglobins, microalbumin in proven diabetes mellitus, or prealbumin — quantitation in serum, urine or other body fluids — 1 test	19.90
66363	2 or more tests described in item 66361	36.65
66367	Quantitation of acetoacetate, alcohol, amino acids, ammonia, angiotensin converting enzyme, beta-hydroxybutyrate, cholinesterase, cysteine, total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, oxalate, pyruvate, serotonin, xylose, or zinc — 1 test	24.35
66369	2 or more tests described in item 66367

38.30
66373	Human placental lactogen or oestriol — quantitation, except if requested as part of item 66321 — 1 test	31.55
66375	2 tests described in item 66373	42.60
66405	Quantitation of hormones and hormone binding proteins — ACTH, aldosterone, androstenedione, C-peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(lgF1), free or total testosterone, TSH (where not requested on its own or as part of a thyroid function test), urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone) — 1 test (Item is subject to rule 6)	31.55
66407	2 tests described in item 66405 (Item is subject to rule 6)	42.55
66409	3 tests described in item 66405 (Item is subject to rule 6)	53.55
66411	4 tests described in item 66405 (Item is subject to rule 6)	64.55
66413	5 tests described in item 66405 (Item is subject to rule 6)	75.55
66415	6 or more tests described in item 66405	86.55
66417	Tests described in item 66405, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 (Item is subject to rule 6)	11.05
66419	Oral glucose tolerance test for the diagnosis of diabetes mellitus that includes the following: (a) administration of glucose; (b) at least 3 estimations of blood glucose; (c) if performed, any test described in item 66405	17.70
Group P3 — Microbiology
69201	Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including: (a) differential cell count (if performed); or (b) examination for dermatophytes; or (c) dark ground illumination; or (d) stained preparation or preparations, using any relevant stain or stains; 1 or more tests	7.35
69203	Microscopy of faeces for parasites using concentration techniques (including the use of appropriate stains) to a maximum of 3 tests taken on separate days, including a service (if performed) described in item 69201 — each test	12.35
69205	Culture and (if performed) microscopy to detect pathogenic micro-organisms (including fungi but excluding viruses), from nasal swabs, throat swabs, eye swabs and ear swabs, including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) the detection of antigens not elsewhere described in this Table; or (c) a service described in item 69201; specimens from 1 or more sites	19.35
69207	Microscopy and culture to detect pathogenic micro-organisms, including fungi but excluding viruses, from: (a) skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens); or (b) specimens of sputum (except when part of item 69213); including (if performed): (c) the detection of antigens not elsewhere specified in this Table; or (d) pathogenic identification and antibiotic susceptibility testing; or (e) a service described in items 69201, 69205 and 73810; 1 or more tests on 1 or more specimens	28.25
69209	Microscopy and culture of postoperative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms (including fungi but excluding viruses) involving aerobic and anaerobic culture and the use of different culture media, and ncluding (if performed): (a) pathogen identification and antibiotic susceptibility testing; (b) the detection of antigens not elsewhere specified in this Table; or	38.30
(c) a service described in item 69201, 69205 or 69207; specimens from 1 or more sites
69211	Culture of faeces for faecal pathogens, involving the use of at least 2 selective or enrichment media and culture in at least 2 different atmospheres and including (if performed): (a) pathogen identification and antibiotic susceptibility testing; (b) the detection of clostridial toxins or antigens not elsewhere specified in this Table; or (c) a service described in item 69201; to a maximum of 3 specimens in any 7-day period — each test	46.45
69213	Microscopy with appropriate stains and culture of 3 specimens of sputum, urine or other body fluids for mycobacteria including (if performed): (a) microscopy and culture of other bacterial pathogens; or (b) pathogen identification and antibiotic susceptibility testing; and (c) a service described in item 69201	64.95
69215	Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed): (a) identification of any cultured pathogen; and (b) necessary antibiotic susceptibility testing; each set of cultures to a maximum of 3 sets	17.00
69217	Urine examination (including serial examination) by any means other than simple culture by dip slide, including: (a) cell count; and (b) culture; and (c) colony count (if performed); and (d) stained preparations; and (e) identification of cultured pathogens; and (f) antibiotic susceptibility testing; and (g) any examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts	20.55
69219	Detection of: (a) the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria, meningitidis, Group B streptococcus respiratory syncytial virus, cryptococcal antigens or Varicella zoster; or (b) Clostridium difficile toxin (except if the ervice described in item 69211 has been performed); 1 or more tests	16.25
69221	Detection of Chlamydia from material obtained directly from a patient (not cultures) — 1 or more tests	9.70
69223	Detection of herpes simplex virus from material btained directly from a patient (not cultures) — 1 or more tests	9.70
69229	Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in the Schedule — 1 test (Item is subject to rule 6)	13.90
69231	2 tests described in item 69229 (Item is subject to rule 6)	21.30
69233	3 tests described in item 69229 (Item is subject to rule 6)	28.70
69235	4 tests described in item 69229 (Item is subject to rule 6)	36.10
69237	5 tests described in item 69229 (Item is subject to rule 6)	43.50
69239	6 or more tests described in item 69229	50.90
69241	Tests described in item 69229, if rendered under request referred to in subparagraph (2) (a) (iii) of rule 6 (Item is subject to rule 6)	7.40
69243	Hepatitis B surface antigen test	13.75
69245	Hepatitis B serology to define the immune status of an individual, including at least hepatitis B surface antibody or hepatitis B core antibody test, and including a service described in item 69243, 69247 or 69249 (if performed)	18.60
69247	Serological tests to identify the agent causing acute hepatitis (must include hepatitis B surface ntigen, hepatitis B core antibody and hepatitis A IgM antibody test and the services described in items 69243, 69245 and 69249)	36.75
69249	Tests performed in the follow-up of a patient with proven hepatitis B, including: (a) hepatitis B surface antigen test; and (b) either: (i) hepatitis Be antigen test; or (ii) hepatitis B surface antibody test, and (c) (if performed) services described in items 69243 and 69245	26.70
69251	Antibiotics or antimicrobial chemotherapeutic agents in serum, urine or other body fluid — quantitation — 1 or more tests	24.35
69253	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including: (a) the determination of 1 of the following: rubella immune status, specific syphilis serology, hepatitis B surface antigen; and (b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)	13.90
69255	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including: (a) the determination of 2 of the following: rubella immune status, specific syphilis serology or hepatitis B surface antigen; (b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)	21.25
69257	Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including: (a) the determination of all 3 of the following: rubella immune status, specific syphilis serology and hepatitis B surface antigen); and (b) a service described in 1 or more of items 69229, 69243 and 69245 (if performed)	28.25
69261	Examination for chlamydia (by culture or by the demonstration of chlamydial nucleic acid using a DNA probe) in material obtained directly from a patient, cluding a service described in item 69221, 69223 or 69263 (if performed)	18.05
69263	Examination for herpes simplex virus of one or more types by culture in material obtained directly from patient, including a service described in item 69221, 69223 or 69261 (if performed)	28.15
69265	Hepatitis C antibody test	13.90
Group P4 — Immunology
71061	Immunoelectrophoresis or immunofixation, of serum, urine or other body fluid, and characterisation of, a paraprotein or cryoglobulin not previously characterised, including a service described in 1 or both of items 66213 and 66215 (if performed) — 1 or more tests	28.80
71063	Immunoelectrophoresis or immunofixation of serum and urine concurrently collected, and characterisation of, a paraprotein not previously characterised — 2 or more tests	43.45
71065	Examination of CSF and serum concurrently collected for the presence of oligoclonal proteins — 2 or more tests	43.45
71067	Quantitation of total immunoglobulins A, G, M or D by any method in serum, urine or other body fluid — 1 test	14.85
71069	2 tests described in item 71067	23.45
71071	3 or more tests described in item 71067	32.05
71073	Quantitation of all 4 immunoglobulin G subclasses, with a maximum of 2 patient episodes in a 12-month period — each patient episode	104.75
71075	Quantitation of immunoglobulin E (total), with a maximum of 2 patient episodes in a 12-month period — each patient episode	26.70
71077	Quantitation of immunoglobulin E (total) in the follow-up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, with a maximum of 6 patient episodes in a 12-month period — each patient episode	26.70
71079	Detection of specific immunoglobulin G or E antibodies to single or multiple potential allergens, with a maximum of 4 patient episodes in a 12 month period — each patient episode	24.10
71081	Quantitation of total haemolytic complement	19.90
71083	Quantitation of complement components C3 and C4 or properdin factor B — 1 test	19.90
71085	2 tests described in item 71083	28.55
71087	3 or more tests described in item 71083	37.20
71089	Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule — 1 test	28.75
71091	2 tests described in item 71089	52.10
71093	3 or more tests described in item 71089	75.45
71097	Antinuclear antibodies — detection in serum or other body fluids, including quantitation if required	25.10
71099	Double-stranded DNA antibodies — quantitation by 1 or more methods other than the Crithidia method	26.20
71101	Antibodies to 1 or more extractable nuclear antigens — detection in serum or other body fluids	17.15
71103	Characterisation of an antibody detected in a service described in item 71101 (including that service)	51.35
71106	Rheumatoid factor — detection by any technique in erum or other body fluids, including quantitation if required	11.15
71109	Antibodies to tissue antigens (acetylcholine eceptor, adrenal cortex, cardiolipin, glomerular basement membrane, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, neutrophil cytoplasm, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) — detection, including quantitation if required, of 1 antibody	34.10
71113	Detection of 2 antibodies described in item 71109	46.80
71115	Detection of 3 antibodies described in item 71109	59.50
71117	Detection of 4 antibodies described in item 71109	72.20
71119	Antibodies to tissue antigens not elsewhere specified in this Table — detection, including quantitation if required, of 1 antibody	17.10
71121	Detection of 2 antibodies specified in item 71119	20.50
71123	Detection of 3 antibodies specified in item 71119	23.90
71125	Detection of 4 or more antibodies specified in item 71119	27.30
71127	Functional tests for lymphocytes — quantitation other than by microscopy of: (a) proliferation induced by 1 or more mitogens; or (b) proliferation induced by 1 or more antigens; or (c) estimation of 1 or more mixed lymphocyte reactions; including a test described in item 65005 (if performed), with a maximum of 2 patient episodes in a 12-month period — each patient episode	174.05
71129	2 tests described in item 71127	215.00
71131	3 or more tests described in item 71127	255.95
71135	Quantitation of neutrophil function, comprising at least 2 of the following: (a) chemotaxis; (b) phagocytosis; (c) oxidative metabolism; (d) bactericidal activity; including any test described in item 65005 (other than nitroblue tetrazolium reduction slide test), with a maximum of 2 patient episodes in a 12-month period — each patient episode	205.25
71137	Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, with a maximum of 2 patient episodes in a 12-month period — each patient episode	29.85
71139	Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid	102.65
71141	Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens	194.80
71143	Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue	256.60
71145	Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed), on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid	418.95
71147	HLA-B27 typing	32.00
71149	Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including a service described in item 71147 (if performed)	106.85
71151	Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) — phenotyping or genotyping of 2 or more antigens	117.30
Group P5 — Tissue pathology
72801	Examination of biopsy material (gross and microscopic) including all tissue processing, staining, and except as provided for in 72805 and 72807 — all professional opinions	79.05
72803	Intraoperative frozen section diagnosis of biopsy material, including any other tissue pathology service in Group P5	148.40
72805	Immunohistochemical staining of biopsy material by 1 or more labelled antibody techniques (including immunofluorescence and immunoperoxidase) and including any other tissue pathology service in Group P5	107.45
72807	Electron microscopy of biopsy material including any other tissue pathology service in Group P5	153.65
Group P6 — Cytology
73043	Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes — 1 or more tests	15.00
73045	Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053); and including any Group P5 service, if performed on: (a) specimens resulting from washings or brushings from sites not specified in item 73043; or (b) a single specimen of sputum or urine; or (c) 1 or more specimens of other body fluids; 1 or more tests	29.35
73047	Cytology of a series of 3 sputum or urine specimens for malignant cells	61.10
73049	Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues	51.75
73051	Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues if: (a) the aspiration is performed by a recognised pathologist; or (b) a recognised pathologist attends the aspiration and performs cytological examination during the attendance	88.85
73053	Cytology of smears from cervix: (a) for detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or (b) due to an unsatisfactory smear taken in the circumstances defined in para (a) above; each examination	13.80
73055	Cytology not associated with item 73053, of smears from cervix in association with: (a) the management of previously detected abnormalities including precancerous or cancerous conditions; or (b) the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia; each test	13.80
73057	Cytology of smears from vagina, not associated with item 73053 or 73055 nor to monitor hormone replacement therapy — each test	13.80
Group P7 — Cytogenetics
73287	Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of one or more of any tissue or fluid except blood — 1 or more tests	327.60
73289	Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of blood — 1 or more tests	296.85
Group P8 — Infertility and pregnancy tests
73521	Semen examination for presence of spermatozoa, or examination of cervical mucus for spermatozoa Huhner’s test)	6.80
73523	Semen examination (other than post-vasectomy semen examination), including: (a) measurement of volume, sperm count, and otility; and (b) examination of stained preparations; and (c) morphology; and (if performed) (d) differential count and 1 or more chemical tests; with a maximum of 4 episodes in a 12-month period — each episode	28.25
73525	Sperm antibodies — sperm-penetrating ability — 1 or more tests	18.20
73527	Chorionic gonadotrophin (beta-HCG) — detection in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy — 1 or more tests	9.90
73529	Chorionic gonadotrophin (beta-HCG) — quantitation n serum by 1 or more methods for diagnosis of hydatidiform mole, HCG-secreting neoplasm, or threatened abortion, or follow-up of abortion or diagnosis of ectopic pregnancy, including any services performed in 73527 — 1 test	28.25
Group P9 — Simple basic pathology tests
73801	Semen examination for presence of spermatozoa	6.50
73802	Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count — 1 test	4.30
73803	2 tests described in item 73802	6.00
73804	3 or more tests described in item 73802	7.70
73805	Microscopy of urine whether stained or not, or catalase test	4.30
73806	Pregnancy test by 1 or more immunochemical methods	9.90
73807	Microscopy for wet film other than urine, including any relevant stain	6.50
73808	Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 7380

8.15
73809	Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method	2.20
73810	Microscopy for fungi in skin, hair or nails — 1 or more sites	6.50
73811	Mantoux test	10.60
Group P10 — Patient episode initiation
73901	Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory	7.85
73903	Initiation of a patient episode that consists only of a service described in item 72801 from a person who is an in-patient of a hospital other than a recognised hospital	14.15
73905	Initiation of a patient episode that consists only of a service described in item 72801 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital	7.85
73907	Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected in a licensed collection centre	16.25
73909	Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital	16.25
73911	Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing or in a nursing home or institution	10.00
73913	Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or 73907 or items in Group P9) if the specimen is collected from the person by the person	10.00
73915	Initiation of a patient episode by collection of a specimen for a service (other than a service described in items 73901, 73903 or 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner	10.00
Group P11 — Specimen referred
73921	Receipt of specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of a different approved pathology authority or another pathology authority (Item is subject to subrule 11 (9))	10.00

Part3Abbreviations

Division AAbbreviations for groups of tests

Group	Tests included in group	Abbreviation	Item numbers
Cardiac enzymes	Lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and creatine kinase (CK)	CE	66205
Coagulation studies	Prothrombin time, activated partial thrombo-plastin time and two or more of the following tests — bleeding time, thrombin clotting time, fibrinogen degradation products, fibrin monomer, D-dimer, factor XIII screening tests	COAG	65035
Electrolytes	Sodium (NA), potassium (K), chloride (Cl), and bicarbonate (HCO3)	E	66207
Lipid studies	Cholesterol (CHOL) and triglycerides (TRIG)	FATS	66331
Liver function tests	Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), bilirubin (BIL), gamma glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), and protein (PROT)	LFT	66211
Syphilis serology	Rapid plasma reagin test (RPR), or venereal disease research laboratory test (VDRL), and treponema pallidum haemagglutination test (TPHA), or fluorescent treponemal antibody-absorption test (FTA)	STS	69231
Urea, electrolytes, creatine	Urea, electrolytes, creatinine	U&E	66211

Division BAbbreviations for individual tests

Test	Abbreviation	Item
Abnormal haemoglobins	AH	65027
Acetoacetate	ACAT	66367
Acetylcholine receptor — tissue antigens — antibodies	ARA	71109
Actinomycetes — microbial antibody testing	ACT	69229
Adenovirus — microbial antibody testing	ADE	69229
Adrenal cortex — tissue antigens — antibodies	ADR	71109
Adrenocorticotrophic hormone (ACTH)	ACTH	66405
AFB microscopy and culture of sputum	AFB	69213
Alanine aminotransferase	ALT	66201
Albumin	ALB	66201
Alcohol (ethanol)	ETOH	66367
Aldosterone	ALDS	66405
Alkaline phosphatase	ALP	66201
Alkaline phosphatase — isoenzymes	ALPI	66249
Alpha fetoprotein	AFP	66353
Alpha fetoprotein — for Down’s syndrome and neural tube defect testing	NTDD	66321
Alpha-1-acid glycoprotein	AAG	66255
Alpha-1-antitrypsin	AAT	66255
Alpha-2-macroglobulin	AMG	66255
Aluminium	AL	62777
Aluminium — renal dialysis	ALR	66325
Amino acids	AA	66367
Amiodarone	AMIO	66235
Amitriptyline	AMIT	66235
Ammonia	NH3	66367
Amylase	AMS	66201
Amylobarb	AMYL	66235
Androstenedione	ANDR	66405
Angiotensin converting enzyme	ACE	66367
Antibiotic and antimicrobial chemotherapeutic agents — quantitation	QAA	69251
Antibodies to extractable nuclear antigens — detection	ENA	71101
Antibodies to extractable nuclear antigens — characterisation of antibodies if positive ENA	ENAP	71103
Antibodies to nuclear antigens — detection	ANA	71097
Antibodies to nuclear antigens — quantitation and measurement of DNA binding if positive ANA	ANAP	71099
Antibodies to tissue antigens — acetylcholine receptor	ARA	71109
Antibodies to tissue antigens — adrenal cortex	ADR	71109
Antibodies to tissue antigens — cardiolipin	ACL	71109
Antibodies to tissue antigens — centromere	ACA	71119
Antibodies to tissue antigens — gastric parietal cell	PCA	71119
Antibodies to tissue antigens — gliadin IgA	GLIA	71119
Antibodies to tissue antigens — glomerular basement membrane	GBA	71109
Antibodies to tissue antigens — heart	AHE	71109
Antibodies to tissue antigens — histone	AHI	71109
Antibodies to tissue antigens — insulin receptor antibodies	INSA	71109
Antibodies to tissue antigens — intercellular cement substance of skin	ICCS	71109
Antibodies to tissue antigens — intrinsic factor	AIF	71109
Antibodies to tissue antigens — islet cell	AIC	71109
Antibodies to tissue antigens — Jo-1	JO1	71119
Antibodies to tissue antigens — keratin	KERA	71119
Antibodies to tissue antigens — liver/kidney microsomes	LKA	71119
Antibodies to tissue antigens — lymphocyte	ALY	71109
Antibodies to tissue antigens — mitochondria	MA	71119
Antibodies to tissue antigens — neuron	ANE	71109
Antibodies to tissue antigens — neutrophil cytoplasm	ANCA	71109
Antibodies to tissue antigens — ovary	AOV	71109
Antibodies to tissue antigens — parathyroid	PTHA	71109
Antibodies to tissue antigens — platelet	APA	71109
Antibodies to tissue antigens — PM-Sc1	PM1	71119
Antibodies to tissue antigens — reticulin	RCA	71119
Antibodies to tissue antigens — salivary gland	ASG	71109
Antibodies to tissue antigens — Scl-70	SCL	71119
Antibodies to tissue antigens — skeletal muscle	SLA	71109
Antibodies to tissue antigens — skin basement membrane	SKA	71109
Antibodies to tissue antigens — smooth muscle	SMA	71119
Antibodies to tissue antigens — thyroglobulin	ATG	71109
Antibodies to tissue antigens — thyroid icrosome	TMA	71109
Antibodies to tissue antigens — TSH receptor antibody test	TSHA	71109
Antibody testing, microbial (see Microbial) Antigen testing, microbial (see Microbial) Antithrombin III	ATH	65037
Anus — cytology on specimens from	SMCY	73043
Apolipoprotein B/A1 ratio	APO	66317
Arginine infusion	ARIN	66297
Arsenic	AS	66277
Aspartate aminotransferase	AST	66201
Aspergillus — microbial antibody testing	ASP	69229
Avian precipitins (bird fancier’s disease) — microbial antibody testing	APP	69229
B12 vitamin	RCF	66267
Barbiturate	BARB	66235
Beryllium	BE	66277
Beta-hydroxybutyrate	BHYB	66367
Beta-2-microglobulin	BMIC	66361
Bicarbonate	HCO3	66201
Bilirubin (all fractions)	BILI	66201
Bilirubin (all fractions) — in urine	UBIL	66213
Bilirubin (all fractions) — neonatal	BILN	66365
Bird fancier’s disease (see avian precipitins)
Blastomyces — microbial antibody testing	BLM	69229
Bleeding time	BT	65029
Blood — compatibility testing	XMAT	65023
Blood — culture	BC	69215
Blood — faecal occult	FOB	66221
Blood — film	BF	65005
Blood — full examination	FBE	65001
Blood — gases	GAS	66225
Blood — group and blood group antibodies	BGAB	65021
Blood — group antibodies	BGA	65025
Blood — group systems	BGS	65019
Blood — grouping-ABO and RH (D antigen)	BG	65017
Blood — viscosity	VISC	65001
Body cavities, aspirations of — microscopy and culture of material from	MCS3	69209
Body fluids — cytology	BFCY	73045
Bone marrow examination — aspirate	BMEA	65015
Bone marrow examination — trephine	BMET	65013
Bordetella pertussis — microbial antibody testing	BOR	69229
Borrelia burgdorferi — microbial antibody testing	BOB	69229
Breath hydrogen test	BHT	66283
Bromide	BRMD	66235
Brucella — microbial antibody testing	BRU	69229
C-l esterase inhibitor — quantitation	CEIQ	66257
C-l esterase inhibitor — functional	CEIF	66258
C-Peptide	CPEP	66405
C-reactive protein	CRP	65001
CA-15.3 antigen	CA15	66261
CA-l9.9 antigen	CA19	66261
CA-125 antigen	C125	66261
Cadmium	CD	66277
Caeruloplasmin	CPLS	66361
Calcitonin	CALT	66405
Calcium (total, dialysed or ionized)	CA	66201
Calculus analysis	CALC	66229
Campylobacter jejuni — microbial antibody testing	CAM	69229
Candida — microbial antibody testing	CAN	69229
Carbamazepine (Tegretol)	CARB	66235
Carboxyhaemoglobin	COHB	65027
Carcinoembryonic antigen	CEA	66261
Cardiac enzymes (see group tests in Division A)
Cardiolipin — tissue antigens — antibodies	ACL	71109
Catecholamines	CAT	66281
Cell mediated immunity — delayed type — hypersensitivity test	CMI	71137
Centromere — tissue antigens — antibodies	ACA	71119
Cervix — cytology — routine	CCR	73053
Cervix — cytology — abnormalities	CCRA	CCRA
Cervix — microscopy and culture of material from	MCS2	69207
Characterisation of antibodies if positive ENA	ENAP	71103
Chemicals, toxic (ingested or absorbed) — assays	DRGO	66231
Chlamydia — direct detection from clinical material	CHLY	69221
Chlamydia —investigation by cultural methods	CHLC	69261
Chlamydia — investigation by DNA probe	CHLP	69261
Chlamydia — microbial antibody testing	CHL	69229
Chlamydia — microbial antigen testing	CHLY	69221
Chloral hydrate	CHHY	66235
Chlorazepate	CHZP	66235
Chloride	CL	66201
Chloroquine	CLOQ	66235
Chlorpromazine	CHLO	66235
Cholesterol	CHOL	66331
Cholesterol — HDL	HDLC	66317
Cholinesterase	CHSE	66367
Chorionic gonadotrophin — for pregnancy diagnosis	HCG	73527
Chorionic gonadotrophin — for diagnosis of specified conditions	HCGD	73529
Chorionic gonadotrophin — for Down’s syndrome and neural tube defect testing	NTDD	66321
Chromium	CR	66277
Chromosome identification and banding	73287-89
Chromosome identification studies — blood	CSB	73289
Chromosome identification studies — other than blood	CS	73287
Cimetidine	CMTD	66235
Clobazam	CLOB	66235
Clomipramine	CLOM	66235
Clonazepam (Rivotril)	CLON	66235
Clostridium difficile — microbial antigen testing	CLD	69219
Coagulation — factors (see individual factors)
Coagulation — studies (see group tests in Division A)
Coagulation — time	CT	65029
Coccidioidesv microbial antibody testing	CCC	69229
Cold agglutinins	CAG	65005, 65027
Collection of specimen(s) for cytological examination	73051
Compatibility testing	XMAT	65023
Complement, total haemolytic	COM	71081
Complement, total haemolytic — components C3	C3	71083
Complement, total haemolytic — components C4	C4	71083
Complement, total haemolytic — properdin-factor B	PFB	71083
Complement, total haemolytic — other components	COMP	71089
Copper	CU	66277
Cortisol	CORT	66405
Coxsackie B1-6 — microbial antibody testing	COX	69229
Creatine kinase	CK	66201
Creatine kinase — isoenzymes	CKI	66201
Creatine kinase — isoenzymes (electrophoresis)	CKIE	66249
Creatinine	C	66201
Cryofibrinogen — qualitative	CFID	66213
Cryofibrinogen — quantitative	CFIE	66215
Cryoglobulins — qualitative	CGLD	66213
Cryoglobulins — quantitative	CGLE	66215
Cryoglobulins — investigation by immunoelectrophoresis or immunofixation	RYO	71061
Cryptococcal antigen — microbial antigen testing	CRYN	69219
Cryptococcus — microbial antibody testing	CRY	69229
CSF — microscopy and culture of material from	MCS3	69209
CSF antigens — group B streptococcus	STB	69219
CSF antigens — Haemophilus influenzae	HI	69219
CSF antigens — Neisseria meningitidis	NMG	69219
CSF antigens — Streptoccus pneumoniae	SPN	69219
Cultural examination of faeces	FCS	69211
Cyclic AMP	CAMP	66405
Cyclosporin A	CLSA	66235
Cystine — qualitative	UCYS	66213
Cystine — quantitative	CYST	66367
Cytology — from body fluids, sputum (1 specimen), urine, washings or brushings	BFCY	73045
Cytology — from cervix — routine	CCR	73053
Cytology — from cervix — abnormalities	CCRA	73055
Cytology — from fine needle aspiration of solid tissues	FNCY	73049
Cytology — from fine needle aspiration of solid tissues — aspiration or attendance by a pathologist	FNCP	73051
Cytology — from skin, nipple discharge, lip, mouth, nose or anus	SMCY	73043
Cytology — from vagina	CVO	73057
Cytology — from 3 sputum or urine specimens	SPCY	73047
Cytomegalovirus — microbial antibody testing	CMV	69229
Cytomegalovirus serology in pregnancy — microbial antibody testing	CMVP	69253-57
D-dimer test	DD	65029
D vitamin	VITD	66271
Dehydroepiandrosterone sulphate (DHEAS)	DHEA	66405
Dengue — microbial antibody testing	DEN	69229
11-Deoxycortisol	DCOR	66405
Desipramine	DESI	66235
Dexamethasone	DXST	66295
Dexamethasone — suppression test	DEXA	66295
DHEAS (Dehydroepiandrosterone sulphate)	DHEA	66405
Diazepam	DIAZ	66235
Differential cell count	DIFF	65005
Digoxin	DIG	66235
Dihydrotesterone	DHTS	66405
Diphenylhydantoin (Dilantin)	DIL	66235
Diphtheria — microbial antibody testing	DIP	69229
Direct Coombs test	CMBS	65005, 65027
Disopyramide (Rythmodan)	DISO	66235
DNA, double-stranded antibodies	DNAD	71099
DNA binding — quantitation and measurement if positive ANA	ANAP	71099
Down’s syndrome and neural tube defects	NTDD	66321
Doxepin hydrochloride	DOXE	66235
Drugs — abuse treatment programme — assay	DATP	66343
Drugs — inappropriate dosage — assay	DRGO	66231
Drugs — therapeutic — assay (see individual drugs) Dynamic function tests	GHSE	66295
Ear — microscopy and culture of material from	MCS1	69205
Echinococcus — microbial antibody testing	ECC	69229
Echo-coxsackie group — microbial antibody testing	ECH	69229
Electrolytes (see group tests in Division A)
Electron microscopy of biopsy material	EM	72807
Electrophoresis, to demonstrate — creatine kinase isoenzymes	CKIE	66249
Electrophoresis, to demonstrate — lactate dehydrogenase isoenzymes	LDI	66249
Electrophoresis, to demonstrate — lipoprotein subclasses	LEPG	66250
Electrophoresis, to demonstrate — protein classes, or paraprotein	EPP1	66249
Electrophoresis, to demonstrate — protein classes or presence and amount of paraprotein classes, concurrent collection	EPP2	66247
Elements (see individual elements)
Entamoeba histolytica — microbial antibody testing	AMO	69229
Enzyme assays of solid tissue or tissues	ENZS	66285
Epstein Barr virus — microbial antibody testing	EBV	69229
Erythrocyte — assessment of haemolysis	ERYH	65009
Erythrocyte — assessment of metabolic enzymes	ERYM	65009
Erythrocyte — count	RCC	65001
Erythrocyte — sedimentation rate	ESR	65001
Ethosuximide (Zarontin)	ETHO	66235
Euglobulin clot lysis time	ECLT	65037
Extractable nuclear antigens — detection of antibodies to	ENA	71101
Eye — microscopy and culture of material from	MCS1	69205
Factor II	FII	65045
Factor V	FV	65045
Factor VI	FVII	65045
Factor VIII	VIII	65045
Factor IX	FIX	65045
Factor X	FX	65045
Factor XI	FXI	65045
Factor XII	FXII	65045
Factor XIII	XIII	65045
Factor XIII deficiency test	F13D	65029
Faecal blood	FOB	66221
Faecal fat	FFAT	66283
Faecal fat — haemoglobin — chemical test	FHC	66217
Faecal fat — haemoglobin — immunological test	FHI	66219
Faecal fat — porphyrins — qualitative test	FPR	66217
Faecal fat — reducing substances	FRS	66217
Faeces — culture	FCS	69211
Faeces — microscopy for parasites	OCP	69203
Fatty acids — total free — quantitation	TFFA	66367
Ferritin (see also Iron studies)	FERR	66355
Fibrin monomer	FM	65029
Fibrinogen	FIB	65029
Fibrinogen — degradation products	FDP	65029
Fitzgerald factor	FGF	65045
Flecainide	FLEC	66235
Fletcher factor	FF	65045
Fluorescent treponemal antibody — absorption test (FTA-ABS) — microbial antibody testing	FTA	69229
Fluoxetine	FLUX	66235
Folate — red cell	RCF	66267
Follicle stimulating hormone (FSH)	FSH	66405
Frozen section diagnosis of biopsy material	FS	72803
Fructosamine	FRUC	66201
Full blood examination	FBE	65007
Gamma glutamyl transpeptidase	GGT	66201
Gastric parietal cell — tissue antigens — antibodies	PCA	71119
Gastrin	GAST	66405
Gliadin IgA — tissue antigens — antibodies	GLIA	71119
Globulin	GLOB	66201
Glomerular basement membrane — tissue antigens — antibodies	GBA	71109
Glucagon	GLGO	66405
Glucagon stimulation test	GSTC	66297
Glucose	GLUC	66201
Glucose — tolerance test	GTT	66419
Glycolated haemoglobin (Hb A1c)	GHB	66319
Glycosylated haemoglobin (Hb A1c)	GHB	66319
Gold	AU	66277
Gonadotrophin	GRHS	66297
Group B streptococcus — CSF antigens	STB	69219
Group B streptococcus — microbial antigen testing	STB	69219
Group P9 — simple basic pathology tests	73801-11
Growth hormone	GH	66405
Growth hormone — stimulation by exercise or L-dopa	GHSE	66295
Growth hormone suppression by dexamethasone or glucose	GHSG	66295
Haematocrit	HCT	65001
Haemoglobin	HB	65001
Haemoglobin — in urine	UHB	66213
Haemoglobinopathy tests	HMGP	65011
Haemophilus influenzae antigens	HI	69219
Haemophilus influenzae — microbial antibody testing	HUS	69229
Haemophilus influenzae — microbial antigen testing	HI	69219
Haloperidol	HALO	66235
Haptoglobins	HGLB	66361
HDL cholesterol	HDLC	66317
Heart — tissue antigens — antibodies	AHE	71109
Heparin — cofactor II	HRNC	65037
Heparin — test	HEPR	65043
Hepatitis delta antibody — anti-delta — microbial antibody testing	HDA	69229
Hepatitis serology — acute hepatitis	HEP	69247
Hepatitis serology — follow-up of proven hepatitis-B	HEPB	69249
Hepatitis serology — hepatitis B serology to define immune status	HEP1	69245
Hepatitis serology — hepatitis B surface antigen HBsAg	HBSA	69243
Hepatitis serology — hepatitis C	HEPC	69265
Hepatitis serology — hepatitis delta antibody	HDA	69229
Hepatitis serology — in pregnancy	HEPP	69253-57
Herpes simplex virus — direct detection from clinical material	HSV	69223
Herpes simplex virus — investigation by culture	HSVC	69263
Herpes simplex virus — microbial antibody testing	HPA	69229
Herpes simplex virus — microbial antigen testing	HSV	69223
Heterophile antibodies	IM	65005, 65027
HIAA (hydroxyindoleacetic acid)	HIAA	66367
Histamine	HIAM	66367
Histone — tissue antigens — antibodies	AHI	71109
Histopathology of biopsy material	HIST	72801
Histoplasma — microbial antibody testing	HIP	69229
HLA typing — HLA-B27	HLAB	71147
HLA typing — HLA class 1	HLA1	71149
HLA typing — HLA class 2	HLA2	71151
HMMA (hydroxy-3-methoxymandelic acid, previously known as VMA)	HMMA	66281
HMPG (hydroxy-methoxy-phenylethylene glycol)	HMPG	66281
Homovanillic acid	HVA	66281
Hormone receptor assay — breast	HRA	66315
Hormone receptor assay — ovary	HRO	66315
Hormones — adrenocorticotrophic	ACTH	66405
Hormones — aldosterone	ALDS	66405
Hormones — androstanedione	ANDR	66405
Hormones — C-Peptide	CPEP	66405
Hormones — calcitonin	CALT	66405
Hormones — cortisol	CORT	66405
Hormones — cyclic AMP	CAMP	66405
Hormones — dehydroepiandrosterone sulphate (DHEAS)	DHEA	66405
Hormones — dihydrotestosterone	DHTS	66405
Hormones — follicle stimulating hormone	FSH	66405
Hormones — gastrin	GAST	66405
Hormones — glucagon	GLGO	66405
Hormones — gonadotrophin	GRHS	66297
Hormones — growth hormone	GH	66405
Hormones — growth hormone — stimulation by exercise or L-dopa	GHSE	66295
Hormones — growth hormone — suppression by dexamethasone or glucose	GHSG	66295
Hormones — hormone receptor assay — breast	HRA	66315
Hormones — hormone receptor assay — ovary	HRO	66315
Hormones — human chorionic gonadotrophin — for pregnancy diagnosis	HCG	73527
Hormones — human chorionic gonadotrophin (see human chorionic gonadotrophin)
Hormones — human placental lactogen	HPL	66373
Hormones — hydroxyprogesterone	OHP	66405
Hormones — insulin	INS	66405
Hormones — insulin, hypoglycaemia test	INHY	66297
Hormones — luteinising hormone	LH	66405
Hormones — oestradiol	E2	66405
Hormones — oestriol	E3	66373
Hormones — oestrone	E1	66405
Hormones — parathyroid hormone	PTH	66405
Hormones — pentagastrin	PSTR	66297
Hormones — progesterone	PROG	66405
Hormones — prolactin	PROL	66405

Hormones — renin	REN	66405
Hormones — sex hormone binding globulin	SHBG	66405
Hormones — somatomedin	SOMA	66405
Hormones — testosterone	TES	66405
Hormones — urine steroid fraction or fractions	USF	66405
Hormones — vasoactive intestinal peptide	VIP	66405
Hormones — vasopressin	ADH	66405
Hormones — 11 deoxycortisol	DCOR	66405
Hormones and hormone binding proteins (see individual hormones and proteins)	66405
Huhner’s test	HT	73521
Human chorionic gonadotrophin — for pregnancy diagnosis	HCG	73527
Human chorionic gonadotrophin — for diagnosis of specified conditions	HCGD	73529
Human chorionic gonadotrophin — for Down’s syndrome and neural tube defect testing	NTDD	66321
Human placental lactogen	HPL	66373
HVA (homovanillic acid)	HVA	66281
Hydatid — microbial antibody testing	HYD	69229
Hydroxy methoxy phenylethylene glycol	HMPG	66281
Hydroxy-3-methoxymandelic acid, previously known as VMA)	HMMA	66281
Hydroxychloroquine	HOCQ	66235
Hydroxyindoleacetic acid	HIAA	66367
Hydroxyprogesterone	OHP	66405
Hydroxyproline	HYDP	66367
Imipramine	IMIP	66235
Immediate frozen-section diagnosis of biopsy material	FS	72803
Immunoglobulins — A	IGA	71067
Immunoglobulins — D	IGD	71067
Immunoglobulins — E (total)	IGE	71075-79
Immunoglobulins — G	IGG	71067
Immunoglobulins — G, 4 subclasses	SIGG	71073
Immunoglobulins — M	IGM	71067
Immunohistochemical investigation of biopsy material	HIS	72805
Infectious mononucleosis	IM	69229
Influenza A — microbial antibody testing	FLA	69229
Influenza B — microbial antibody testing	FLB	69229
Insulin	INS	66405
Insulin — hypoglycaemia test	INHY	66297
Insulin — tissue antigens — antibodies	AINS	71109
Insulin receptor antibodies — tissue antigens — antibodies	INSA	71109
Intercellular cement substance of skin — tissue antigens — antibodies	ICCS	71109
Intestinal	INTD	66283
Intrinsic factor — tissue antigens — antibodies	AIF	71109
Iron studies (iron, transferrin and ferritin)	IS	66263
Islet cell — tissue antigens — antibodies	AIC	71109
Jo-1 — tissue	JO1	71119
Keratin — tissue	KERA	71119
L-dopa	GHLD	66295
Lactate	LACT	66367
Lactate — dehydrogenase	LDH	66201
Lactate — dehydrogenase isoenzymes	LDI	66249
Lamellar body phospholipid	LBPH	66243
Lead	PB	66279
Lecithin/sphingomyelin ratio (amniotic fluid)	LS	66243
Legionella pneumophila — serogroup 1 — microbial antibody testing	LP1	69229
Legionella pneumophila — serogroup 2 — microbial antibody testing	LP2	69229
Leishmaniasis — microbial antibody testing	LEI	69229
Leptospira — microbial antibody testing	LEP	69229
Leucocyte count	WCC	65001
Leucocyte — 3 surface markers — blood, CSF, serous fluid	LMH3	71139
Leucocyte — 3 surface markers — tissue	LMT3	71141
Leucocyte — 6 surface markers — blood, CSF, serous fluid or tissue	LM6	71143
Leucocyte — 6 surface markers— blood, CSF, serous fluid and tissue (s)	LMHT	71145
Lignocaine	LIGN	66235
Lip — cytology on specimens from	SMCY	73043
Lipase	LIP	66201
Lipid studies (see group tests in Division A)
Lipoprotein electrophoresis	LEPG	66250
Listeria — microbial antibody testing	LIS	69229
Lithium	LI	66201
Liver function tests (see group tests)	LFT	66211
Liver/kidney microsomes — tissue antigens — antibodies	LKA	71119
Lupus anticoagulant	LUPA	65037
Luteinising hormone	LH	66405
Lymphocyte — tissue antigens — antibodies	ALY	71109
Lymphocytes — functional tests — 1 test	LF1	71127
Lymphocytes — functional tests — 2 tests	LF2	71129
Lymphocytes — functional tests — 3 tests	LF3	71131
Magnesium	MG	66201
Mammary serum antigen	MSA	66261
Manganese	MN	66277
Mantoux test	MANT	73811
Measles — microbial antibody testing	MEA	69229
Melanogen (see Urine melanin)
Mercury	HG	66277
Metalbumin detection (Schumm’s test)	SCHM	65027
Metanephrines	MNEP	66281
Methadone	MTDN	66235
Methotrexate	MTTA	66235
Methsuximide	MSUX	66235
Metronidazole	MRDZ	66235
Mexiletine (Mexitil)	MEX	66235
Mianserin	MIAS	66235
Microalbumin	MALB	66361
Microbial antibody testing — actinomycetes	ACT	69229
Microbial antibody testing — adenovirus	ADE	69229
Microbial antibody testing — aspergillus	ASP	69229
Microbial antibody testing — avian precipitins (see avian precipitions)
Microbial antibody testing — Blastomyces	BLM	69229
Microbial antibody testing — Bordetella pertussis	BOR	69229
Microbial antibody testing — Borrelia burgdorferi	BOB	69229
Microbial antibody testing — Brucella	BRU	69229
Microbial antibody testing — Campylobacter jejuni	CAM	69229
Microbial antibody testing — Candida	CAN	69229
Microbial antibody testing — Chlamydia	CHL	69229
Microbial antibody testing — Coccidioides	CCC	69229
Microbial antibody testing — Coxsackie B1-6	COX	69229
Microbial antibody testing — cryptococcus	CRY	69229
Microbial antibody testing — cytoMegalovirus	CMV	69229
Microbial antibody testing — cytomegalovirus serology in pregnancy	CMVP	69253-57
Microbial antibody testing — dengue	DEN	69229
Microbial antibody testing — diphtheria	DIP	69229
Microbial antibody testing — echinococcus	ECC	69299
Microbial antibody testing — echo-coxsackie group	ECH	69229
Microbial antibody testing — Entamoeba histolytica	AMO	69229
Microbial antibody testing — Epstein Barr virus	EBV	69229
Microbial antibody testing — fluorescent treponemal antibody — absorption test (FTA-ABS)	FTA	69229
Microbial antibody testing — Haemophilus influenzae	HUS	69229
Microbial antibody testing — hepatitis C	HEPC	69265
Microbial antibody testing — hepatitis delta antibody — anti-delta	HDA	69229
Microbial antibody testing — herpes	HPA	69229
Microbial antibody testing — Histoplasma	HIP	69229
Microbial antibody testing — hydatid	HYD	69229
Microbial antibody testing — infectious Mononucleosis	IM	69229
Microbial antibody testing — influenza A	FLA	69229
Microbial antibody testing — influenza B	FLB	69229
Microbial antibody testing — serogroup 1	LP1	69229
Microbial antibody testing — Legionella pneumophila — serogroup 2	LP2	69229
Microbial antibody testing — leishmaniasis	LEI	69229
Microbial antibody testing — Leptospira	LEP	69229
Microbial antibody testing — Listeria	LIS	69229
Microbial antibody testing — Measles	MEA	69229
Microbial antibody testing — Micropolyspora faeni	MIC	69229
Microbial antibody testing — mumps	MUM	69229
Microbial antibody testing — Murray Valley encephalitis	MVE	69229
Microbial antibody testing — Mycoplasma pneumoniae	MYC	69229
Microbial antibody testing — Neisseria menigitidis	MEN	69229
Microbial antibody testing — Newcastle disease	NCD	69229
Microbial antibody testing — parainfluenza 1	PF1	69229
Microbial antibody testing — parainfluenza 2	PF2	69229
Microbial antibody testing — parainfluenza 3	PF3	69229
Microbial antibody testing — paratyphi	PTY	69229
Microbial antibody testing — pertussis	PER	69229
Microbial antibody testing — poliomyelitis	PLO	69229
Microbial antibody testing — Proteus OX 19	POX	69229
Microbial antibody testing — Proteus OXK	POK	69229
Microbial antibody testing — Q fever	QFF	69229
Microbial antibody testing — rapid plasma reagin test	RPR	69229
Microbial antibody testing — respiratory syncytial virus	RSV	69229
Microbial antibody testing — Ross River virus	RV	69229
Microbial antibody testing — rubella	RUB	69229
Microbial antibody testing — Salmonella typhi (H)	SAH	69229
Microbial antibody testing — Salmonella typhi (O)	SAO	69229
Microbial antibody testing — Schistosoma	STO	69229
Microbial antibody testing — streptococcal serology — anti-DNASE B titre	ADNB	69229
Microbial antibody testing — streptococcal serology — anti-streptolysin O titre	ASOT	69229
Microbial antibody testing — Streptococcus pneumoniae	PCC	69229
Microbial antibody testing — tetanus	TET	69229
Microbial antibody testing — Thermoactinomyces vulgaris	THE	69229
Microbial antibody testing — thermopolyspora	TPS	69229
Microbial antibody testing — Toxocara	TOC	69229
Microbial antibody testing — toxoplasma	TOX	69229
Microbial antibody testing — TPHA (Treponema pallidum haemagglutination test)	TPHA	69229
Microbial antibody testing — trichinosis	TOS	69229
Microbial antibody testing — typhus, Weil-Felix	TYP	69229
Microbial antibody testing — Varicella zoster	VCZ	69229
Microbial antibody testing — VDRL (Venereal Disease Research Laboratory)	VDRL	69229
Microbial antibody testing — Yersinia enterocolitica	YER	69229
Microbial antigen testing — Chlamydia	CHLY	69221
Microbial antigen testing — Clostridium difficile	CLDT	69219
Microbial antigen testing — group B streptococcus	STB	69219
Microbial antigen testing — Haemophilus influenzae	HI	69219
Microbial antigen testing — herpes simplex virus	HSV	69263
Microbial antigen testing — Neisseria gonorrhoeae	GON	69219
Microbial antigen testing — Neisseria meningitidis	NMG	69219
Microbial antigen testing — respiratory syncytial virus	RSVN	69219
Microbial antigen testing — Streptococcus pneumoniae	SPN	69219
Microbial antigen testing — Varicella zoster	VCZN	69219
Micropolyspora faeni	MIC	69229
Microscopic examination of — faeces for parasites	OCP	69203
Microscopic examination of — material other than blood	M	69201
Microscopy and culture of — material from nose, throat, eye or ear	MCS1	69205
Microscopy and culture of — material from skin, superficial sites, urethra, vagina, cervix or rectum	MCS2	69207
Microscopy and culture of — post-op wounds, aspirations of body cavities, synovial fluid, CSF and op/biopsy specimens	MCS3	69209
Microscopy and culture of — specimens of sputum	MCS2	69207
Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria	AFB	69213
Microscopy, culture, identification and sensitivity of urine	UMCS	69217
Mitochondria — issue antigens — antibodies	MA	71119
Mouth — cytology on specimens from	SMCY	73043
Mucin-like carcinoma-associated antigen	MCA1	66261
Mumps — microbial antibody testing	MUM	69229
Murray Valley encephalitis — microbial antibody testing	MVE	69229
Mycobacteria microscopy and culture of sputum	AFB	69213
Mycoplasma pneumoniae — microbial antibody testing	MYC	69229
Myoglobin in urine	UMY	66213
N-acetyl procainamide	NAPC	66235
Neisseria gonorrhoeae — microbial antigen testing	GON	69219
Neisseria menigitidis antigen	NMG	69219
Neisseria menigitidis — microbial antibody testing	MEN	69229
Neisseria menigitidis — microbial antigen testing	NMG	69219
Neural tube defects and Down’s syndrome	NTDD	66321
Neuron — tissue antigens — antibodies	ANE	71109
Neuron specific enolase	NSEN	66261
Neutrophil cytoplasm — tissue antigens — antibodies	ANCA	71109
Neutrophil functions	NFT	71135
Newcastle disease — microbial antibody testing	NCD	69229
Nickel	NI	66277
Nipple discharge — cytology on specimens from	SMCY	73043
Nitrazepam	NITR	66235
Nordothiepin	NDIP	66235
Norfluoxetine	NFLE	66235
Nortriptyline	NORT	66235
Nose — cytology on specimens from	SMCY	73043
Nose — microscopy and culture of material	MCS1	69205
Nuclear antigens — detection of antibodies to	ANA	71097
Oestradiol	E2	66405
Oestriol	E3	66373
Oestriol — for Down’s syndrome and neural tube defect testing	NTDD	66321
Oestrone	E1	66405
Oligoclonal proteins	OGP	71065
Op/biopsy specimens — microscopy and culture of material from	MCS3	69209
Osmolality — serum or urine	OSML	66223
Ovary — tissue antigens — antibodies	AOV	71109
Oxalate	OXAL	66367
Oxazepam	OXAZ	66235
PAA (phenyl acetic acid)	PAA	66281
Palmitic acid in amniotic fluid	PALM	66243
Pap smear	CCR	73053
Papanicolaou test	CCR	73053
Paracetamol	PARA	66235
Parainfluenza 1 — microbial antibody testing	PF1	69229
Parainfluenza 2 — microbial antibody testing	PF2	69229
Parainfluenza 3 — microbial antibody testing	PF3	69229
Paraprotein investigation — by electrophoresis	EPPI	66249
Paraprotein investigation — by immunoelectrophoresis or immunofixation	PPRO	71061
Paraprotein investigation — on concurrently collected serum or urine	PPSU	71063
Paraquat	PARQ	66235
Parasites — microscopic examination of faeces	OCP	69203
Parathyroid hormone (PTH)	PTH	66405
Parathyroid — tissue antigens — antibodies	PTHA	71109
Paratyphi — microbial antibody testing	PTY	69229
Partial thromboplastin time	PTT	65029
Passovy factor	PF	65045
Patient episode initiation	PEI	73901-15
Pentagastrin	PSTR	66297
Pentobarbitone	PENT	66235
Perhexiline	PHEX	66235
Pertussis — microbial antibody testing	PER	69229
pH measurement of body fluids other than urine	PH	66213
Phenobarbitone	PHBA	66235
Phensuximide	PHEN	66235
Phenylacetic acid	PAA	66281
Phenytoin	PHEY	66235
Phosphate	PHOS	66201
Phosphatidylglycerol	PTGL	66243
Plasminogen	PLAS	65037
Platelet aggregation	PLTG	65041
Platelet — count	PLTC	65001
Platelet — tissue antigens — antibodies	APA	71109
PM-Sc1 — tissue antigens — antibodies	PM1	71119
Poliomyelitis — microbial antibody testing	PLO	69229
Porphobilingen in urine	UPG	66213
Porphyrins — quantitative test, 1 or more fractions	PR	66281
Porphyrins in urine — qualitative test	UPR	66213
Potassium	K	66201
Prealbumin	PALB	66361
Prednisolone	PRED	66235
Pregnancy serology — 1 test	MSP1	69253
Pregnancy serology — 2 tests	MSP2	69255
Pregnancy serology — 3 tests	MSP3	69257
Pregnancy testing	73805
Pregnancy testing — diagnosis	HCG	73527
Pregnancy testing — diagnosis of specified conditions	HCGD	73529
Pregnancy testing — for diagnosis of Down’s syndrome and neural tube defect	NTDD	66321
Primidone	PRIM	66235
Procainamide	PCAM	66235
Progesterone	PROG	66405
Prolactin	PROL	66405
Prominal	PROM	66235
Propranolol	PPNO	66235
Prostate specific antigen	PSA	66357
Prostatic acid phosphatase	ACP	66357
Protein — C	PROC	65037
Protein — S	PROS	65037
Protein, quantitation of — alpha fetoprotein	AFP	66353
Protein, quantitation of — alpha fetoprotein — for Down’s syndrome and neural tube defect testing	NTDD	66321
Protein, quantitation of — alpha-l-antitrypsin	AAT	66255
Protein, quantitation of — alpha-2-macroglobulin	AMAC	66255
Protein, quantitation of — beta-2-microglobulin	BMIC	66361
Protein, quantitation of — C-l esterase inhibitor	CEI	66257
Protein, quantitation of — caeruloplasmin	CPLS	66361
Protein, quantitation of — classes by electrophoresis	EPPI	66249
Protein, quantitation of — ferritin (see also Iron studies)	FERR	66355
Protein, quantitation of — haptoglobins	HGLB	66361
Protein, quantitation of — microalbumin	MALB	66361
Protein, total — quantitation of	PROT	66201
Proteus OX 19 — microbial antibody testing	POX	69229
Proteus OXK — microbial antibody testing	POK	69229
Prothrombin time	PT	65029
Pyruvate	PVTE	66367
Q fever — microbial antibody testing	QFF	69229
Quinalbarb	QUIB	66235
Quinidine	QUIN	66235
Quinine	QNN	66235
Rapid plasma reagin test — microbial antibody testing	RPR	69229
RAST	RAST	71079
Rectum — microscopy and culture of material from	MCS2	69207
Red cell folate and serum B12 and serum folate if required	RCF	66267
Red cell porphyrins — qualitative test	RCP	65027
Referred specimen fee	73921
Renin	REN	66405
Respiratory syncytial virus — microbial antibody testing	RSV	69229
Respiratory syncytial virus — microbial antigen testing	RSVN	69219
Reticulin — tissue antigens — antibodies	RCA	71119
Reticulocyte count	RETC	65001
Rheumatoid factor	RF	71106
Rheumatoid factor — quantitation	RFQ	71106
Ross River virus — microbial antibody testing	RRV	69229
RSV (respiratory syncytial virus) — microbial antigen testing	RSVN	69219
RSV (respiratory syncytial virus) — microbial antibody testing	RSV	69229
Rubella — serology	RUB	69229
Salicylate — aspirin	SALI	66235
Salivary gland — tissue antigens — antibodies	ASG	71109
Salmonella typhi (H) — microbial antibody testing	SAH	69229
Salmonella typhi (O) — microbial antibody testing	SAO	69229
Schistosoma — microbial antibody testing	STO	69229
Scl-70 — tissue antigens — antibodies	SCL	71119
Secretin	SSGR	66297
Selenium	SE	66277
Semen examination	SEE	73523
Semen examination — for spermatozoa (post vasectomy)	SES	73521
Serology — in pregnancy (see Pregnancy serology)
Serotonin	5HT	66367
Serum — B12	B12	66265
Serum — folate (with Bl2)	FOL	66265
Serum — folate (with Bl2 red cell folate)	RCF	66267
Sex hormone binding globulin	SHBG	66405
Skeletal muscle — tissue antigens — antibodies	SLA	71109
Skin — cytology	SMCY	73043
Skin — microscopy and culture of material from	MCS2	69207
Skin basement membrane — tissue antigens — antibodies	SKA	71109
Snake venom	HISS	66231
Smooth muscle — tissue antigens — antibodies	SMA	71119
Sodium	NA	66201
Solid tissue or tissues — chemical assays	ENZS	66285
Solid tissue or tissues — cytology of fine needle aspiration	FNCY	73049
Solid tissue or tissues — cytology of fine needle aspiration by, or in presence of, pathologist	FNCP	73051
Somatomedin	SOMA	66405
Sotalol	SALL	66235
Specific IgG or IgE antibodies	RAST	71079
Specimen referred fee	73921
Sperm antibodies	SAB	73525
Sperm antibodies — penetrating ability	SPA	73525
Sputum — cytology (1 specimen)	BFCY	73045
Sputum — cytology (3 specimens)	SPCY	73047
Sputum — microscopy and culture of specimens	MCS2	69207
Sputum — for mycobacteria	AFB	69213
Stelazine	STEL	66235
Steroid fraction or fractions in urine	USF	66405
Streptococcal serology — anti-DNASE B titre — microbial antibody testing	ADNB	69229
Streptococcal serology — anti-streptolysin O titre — microbial antibody testing	ASOT	69229
Streptococcus — Group B	STB	69219
Streptococcus pneumoniae — antigens	SPN	69219
Streptococcus pneumoniae — microbial antibody testing	PCC	69229
Streptococcus pneumoniae — microbial antigen testing	SPN	69219
Strontium	SR	66277
Sulthiame (Ospolot)	SUL	66235
Synacthen stimulation test	SYNS	66297
Syphilis serology (see group tests)	STS	69231
Testosterone	TES	66405
Tetanus — microbial antibody testing	TET	69229
Thalassaemia studies	TS	65011
Theophylline	THEO	66235
Thermoactinomyces vulgaris — microbial antibody testing	THE	69229
Thermopolyspora — microbial antibody testing	TPS	69229
Thiopentone	TOPO	66235
Thioridazine	THIO	66235
Throat — microscopy and culture of material from	MCS1	69205
Thrombin time	TT	65029
Thyroglobulin	TGL	66261
Thyroglobulin — tissue antigens — antibodies	ATG	71109
Thyroid function tests (including TSH)	TFT	66329
Thyroid stimulating hormone (if requested on its own, or as a preliminary test to thyroid function testing)	TSH	66327
Thyroid stimulating hormone (if requested with other hormones referred to in item 66405))	TSH	66405
Thyroid microsome — tissue antigens — antibodies	TMA	71109
Thyrotrophin releasing hormone test	TRH	66293
Total free fatty acids	TFFA	66367
Total protein	PROT	66201
Toxocara — microbial antibody testing	TOC	69229
Toxoplasma — microbial antibody testing	TOX	69229
TPHA (Treponema pallidum haemagglutination test) — microbial antibody testing	TPHA	69229
Treponema pallidum haemagglutination test — microbial antibody testing	TPHA	69229
Trichinosis — microbial antibody testing	TOS	69229
Triglycerides	TRIG	66331
Trimipramine	TRIM	66235
Tryptic activity in faeces	TAF	66323
TSH receptor antibody test — tissue antigens — antibodies	TSHA	71109
Tuberculosis	MAN	73811
Tumour markers — CA-15.3 antigen	CA15	66261
Tumour markers — CA-19.9 antigen	CA19	66261
Tumour markers — CA-125 antigen	C125	66261
Tumour markers — carcinoembryonic antigen	CEA	66261
Tumour markers — mammary serum antigen	MSA	66261
Tumour markers — mucin-like carcinoma associated antigen	MCA	66261
Tumour markers — neuron specific enolase	NSEN	66261
Tumour markers — prostate specific antigen	PSA	66357
Tumour markers — prostatic acid phosphatase-1 or more fractions	ACP	66357
Tumour markers — thyroglobulin	TGL	66261
Typhus, Weil-Felix — microbial antibody testing	TYP	69229
Urate	URAT	66201
Urea	U	66201
Urea, electrolytes, creatinine (see group tests in Division A)
Urethra — microscopy and culture of material from	MCS2	69207
Urine — bilirubin	UBIL	66213
Urine — catalase test	73805
Urine — cytology — on 1 specimen	BFCY	73045
Urine — cytology — on 3 specimens	SPCY	73047
Urine — cystine (cysteine)	UCYS
Urine — haemoglobin	UHB	66213
Urine — melanin (melanogen)	UML	66213
Urine — microscopy, culture, identification and sensitivity	UMCS	69217
Urine — myoglobin	UMY	66213
Urine — porphobilinogen	UPG	66213
Urine — porphyrins — qualitative test	UPR	66213
Urine — steroid fraction or fractions	USF	66405
Urine — urobilinogen	UUB	66213
Vagina — cytology on specimens from	CVO	73057
Vagina — microscopy and culture of material from	MCS2	69207
Valproate (Epilim)	VALP	66235
Vancomycin	VAN	66235
Varicella zoster — microbial antibody testing	VCZ	69229
Varicella zoster — microbial antigen testing	VCZN	69219
Vasoactive intestinal peptide	VIP	66405
Vasopressin	ADH	66405
VDRL (Venereal Disease Research Laboratory) — microbial antibody testing	VDRL	69229
Viscosity of blood or plasma	VISC	65001
Vitamins — B12	RCF	66267
Vitamins — D	VITD	66271
Vitamins — folate	RCF	66267
Vitamins — quantitation of A, B1, B2, B3, B6, C or E	VIT	66269
VMA (see HMMA)
Von Willebrand’s factor	VWF	65045
Von Willebrand’s factor antigen	VWA	65045
Warfarin	WFR	66235
Xylose	XYL	66367
Yersinia enterocolitica — microbial antibody testing	YER	69229
Zinc	ZN	66367

Notes to the Health Insurance (1994-1995 Pathology Services Table) Regulations

Note 1

The Health Insurance (1994-1995 Pathology Services Table) Regulations (in force under the Health Insurance Act 1973) as shown in this compilation comprise Statutory Rules 1994 No. 233 amended as indicated in the Tables below.

Table of Statutory Rules

Year and number	Date of notification in Gazette	Date of commencement	Application, saving or transitional provisions
1994 No. 233	30 June 1994	1 July 1994
1994 No. 361	31 Oct 1994	1 Nov 1994	—
1995 No. 133	15 June 1995	1 July 1995	—
1995 No. 155	29 June 1995	1 July 1995	—
1995 No. 281	28 Sept 1995	28 Sept 1995	—

Table of Amendments

ad. = added or inserted am. = amended rep. = repealed rs. = repealed and substituted
Provision affected	How affected
Schedule.................................	am. 1994 No. 361; 1995 Nos. 133 and 155